Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 10;17(1):6.
doi: 10.1186/s13014-021-01978-0.

Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer

Wenjuan Chen #  1 , Siyi Xiu #  2 , Xingyun Xie  2 , Huiming Guo  2 , Yuanji Xu  2 , Penggang Bai  2 , Xiaoyi Xia  2
Affiliations

Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer

Wenjuan Chen et al. Radiat Oncol. .

Abstract

Objective: To investigate the prognostic relevance of specific measurement parameters such as tumor diameter, tumor volume, tumor volume reduction rate (TVRR), and changes in the squamous cell carcinoma antigen (SCC-Ag) level in patients with locally-advanced cervical cancer (LACC) undergoing concurrent radiotherapy and chemotherapy.

Methods: This was a retrospective study of 203 patients with stage IIA-IVA cervical squamous cell carcinoma who were newly diagnosed at our hospital between January 2011 and March 2015. Clinical data and pre-and post-treatment imaging information were collected and each parameter was calculated using 3DSlicer software. The pre/post-treatment tumor diameter (TDpre/post), tumor volume (TVpre/post), SCC-Ag (SCCpre/post), and TVRR, SCC-Ag reduction rate (SCCRR) were analyzed and their prognostic relevance evaluated.

Results: The median follow-up was 69 months. The 5-year overall survival (OS) and disease progression-free survival (PFS) rates were 69.5% and 64.5%, respectively. On univariate analysis, TDpre/post, TVpre/post, TVRR, SCCpre/post and SCCRR showed significant association with OS and PFS (P < 0.05). On multivariate analysis, TDpre [Hazard ratio (HR) = 0.373, P = 0.028], TDpost (HR = 0.376, P = 0.003) and SCCpost (HR = 0.374, P = 0.001) were independent predictors of OS. TVRR (HR = 2.998, P < 0.001), SCCpre (HR = 0.563, P = 0.041), and SCCpost (HR = 0.253, P < 0.001) were independent predictors of PFS. Tumor measurement parameters showed a positive correlation with SCC-Ag (P < 0.05).

Conclusion: TDpre/post, TVpre/post, TVRR, SCCpre/post, and SCCRR were prognostic factors in LACC. TDpre/post and SCCpost showed the most significant prognostic value. TVRR and SCCpre/post were closely related to disease progression. Further studies should investigate the correlation between measurement parameters of tumor and SCC-Ag.

Keywords: Cervical cancer; Squamous cell carcinoma antigen (SCC-Ag); Tumor diameter; Tumor volume; Tumor volume reduction rate.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Survival analysis. a Overall survival (OS) and b progression-free survival (PFS)
Fig. 2
Fig. 2
Results of receiver operating characteristic (ROC) curve analysis: a TDpre; b TDpost; c TVpre; d TVpost; e TVRR; f SCCpre; g SCCpost; h age
Fig. 3
Fig. 3
Results of correlation analysis: a Correlation between TDpre and SCCpre; b TDpost and SCCpost; c TVpre and SCCpre; d TVpost and SCCpost; e TVRR and SCCRR
See this image and copyright information in PMC

References

    1. Small W, Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–2412. doi: 10.1002/cncr.30667. - DOI - PubMed
    1. Shrivastava S, Mahantshetty U, Engineer R, Tongaonkar H, Kulkarni J, Dinshaw K. Treatment and outcome in cancer cervix patients treated between 1979 and 1994: a single institutional experience. J Cancer Res Ther. 2013;9(4):672–679. doi: 10.4103/0973-1482.126480. - DOI - PubMed
    1. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical cancer, Version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2019;17(1):64–84. doi: 10.6004/jnccn.2019.0001. - DOI - PubMed
    1. Mazzola R, Ricchetti F, Fiorentino A, Levra NG, Fersino S, Di Paola G, Ruggieri R, Alongi F. Weekly cisplatin and volumetric-modulated arc therapy with simultaneous integrated boost for radical treatment of advanced cervical cancer in elderly patients: feasibility and clinical preliminary results. Technol Cancer Res Treat. 2017;16(3):310–315. doi: 10.1177/1533034616655055. - DOI - PMC - PubMed
    1. Luvero D, Plotti F, Aloisi A, Capriglione S, Ricciardi R, Miranda A, Lopez S, Scaletta G, De Luca G, Benedetti-Panici P, Angioli R. Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up. Med Oncol (Northwood, London, England) 2016;33(10):110. doi: 10.1007/s12032-016-0830-0. - DOI - PubMed

MeSH terms